The study of the biology and function of B cells, or the dissection and in vitro creation of enormous recombinant antibody repertoires, requires the isolation of large numbers of pure CD19+ B cells. The StraightFrom Leukopak CD19 MicroBead Kit was recently introduced as a fast and robust kit to isolate human CD19+ B cells. This uses paramagnetic microbeads conjugated to high-affinity anti-CD19 monoclonal antibodies to bind B cells in leukapheresis (Leukopak) samples. The overall purity of the isolated cells, together with the characterization of the different CD19+ subclasses, was assessed by flow cytometry using a recombinant (REAffinity) antibody panel, revealing that the method allowed the recovery of over 93% of CD19+ B cells without any pre-purification step. This enables the relatively straightforward purification of all the circulating CD19+ B cells in a single donor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nbt.2018.05.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Changes of Lymphocytes and Immune Molecules in Irradiated Mice by Different Doses of Radiation.
Health Phys
January 2025
Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, China.
The effects of different radiation doses on T and B lymphocyte functional subsets and the changes of immune cells and immune molecules were observed in mice at different times post-irradiation to provide a theoretical basis for the changes of immune cells affected by radiation. In this study, the changes of T and B immune cells and immune-related molecules were observed at 1, 3, 7, 14, and 21 d after single irradiation of 2 Gy, 4 Gy, and 6 Gy. The results showed that white blood cells (WBC), lymphocytes (LYMPH), and lymphocyte percentage (LYMPH%) in peripheral blood of mice were significantly reduced and reached the lowest point 3 d after irradiation.
View Article and Find Full Text PDFThe impact of CD3ζ ITAM multiplicity and sequence on CAR T-cell survival and function.
Front Immunol
January 2025
Department of Pathology, University of Utah, Salt Lake City, UT, United States.
Introduction: Chimeric antigen receptor (CAR) expressing T-cells have shown great promise for the future of cancer immunotherapy with the recent clinical successes achieved in treating different hematologic cancers. Despite these early successes, several challenges remain in the field that require to be solved for the therapy to be more efficacious. One such challenge is the lack of long-term persistence of CD28 based CAR T-cells in patients.
View Article and Find Full Text PDFResults From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma.
J Clin Oncol
January 2025
Center for Cell Engineering, Sloan Kettering Institute, New York, NY.
Purpose: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that 1XX CARs generated potent effector function without undermining T-cell persistence. We hypothesized that 1XX CAR T cells may be effective at low doses and elicit minimal toxicities.
View Article and Find Full Text PDF[Rheumatology: what's new in 2024].
Rev Med Suisse
January 2025
Service de rhumatologie, HFR Fribourg, 1708 Fribourg.
In 2024, CD19-CAR T cells are ubiquitous in rheumatology, with incredible therapeutic results in cases of severe and refractory disease. This major advance confirms the interest of the B lymphocyte as a therapeutic target, and also suggests the real possibility of a drug-free remission, at the price of minor and minimal side effects for the time being. However, the necessary perspective is still lacking for a therapy that remains out of reach because of its price.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!